MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
53.06
-0.22
-0.41%
After Hours: 53.06 0 0.00% 17:36 05/08 EDT
OPEN
53.89
PREV CLOSE
53.28
HIGH
53.89
LOW
52.28
VOLUME
1.97M
TURNOVER
--
52 WEEK HIGH
72.83
52 WEEK LOW
39.97
MARKET CAP
10.01B
P/E (TTM)
-9.6474
1D
5D
1M
3M
1Y
5Y
1D
Sum Up The Parts: VONG Could Be Worth $115
NASDAQ · 17h ago
Fidelity Select Health Care Portfolio Q1 2025 Commentary
Seeking Alpha · 1d ago
Exact Sciences (EXAS) Gets a Buy from Scotiabank
TipRanks · 2d ago
Piper Sandler Reaffirms Their Buy Rating on Exact Sciences (EXAS)
TipRanks · 2d ago
Weekly Report: what happened at EXAS last week (0428-0502)?
Weekly Report · 3d ago
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Benzinga · 4d ago
Exact Sciences Corp Reports Strong Start to 2025
TipRanks · 6d ago
Exact Sciences Is Maintained at Overweight by Barclays
Dow Jones · 6d ago
More
About EXAS
More
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Recently
Symbol
Price
%Change

Webull offers Exact Sciences Corp stock information, including NASDAQ: EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.